TY - JOUR T1 - Practical considerations for measuring the effective reproductive number, <em>R<sub>t</sub></em> JF - medRxiv DO - 10.1101/2020.06.18.20134858 SP - 2020.06.18.20134858 AU - Katelyn M. Gostic AU - Lauren McGough AU - Ed Baskerville AU - Sam Abbott AU - Keya Joshi AU - Christine Tedijanto AU - Rebecca Kahn AU - Rene Niehus AU - James Hay AU - Pablo de Salazar AU - Joel Hellewell AU - Sophie Meakin AU - James Munday AU - Nikos I. Bosse AU - Katharine Sherrat AU - Robin N. Thompson AU - Laura F. White AU - Jana S. Huisman AU - Jérémie Scire AU - Sebastian Bonhoeffer AU - Tanja Stadler AU - Jacco Wallinga AU - Sebastian Funk AU - Marc Lipsitch AU - Sarah Cobey Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/23/2020.06.18.20134858.abstract N2 - Estimation of the effective reproductive number, Rt, is important for detecting changes in disease transmission over time. During the COVID-19 pandemic, policymakers and public health officials are using Rt to assess the effectiveness of interventions and to inform policy. However, estimation of Rt from available data presents several challenges, with critical implications for the interpretation of the course of the pandemic. The purpose of this document is to summarize these challenges, illustrate them with examples from synthetic data, and, where possible, make methodological recommendations. For near real-time estimation of Rt, we recommend the approach of Cori et al. (2013), which uses data from before time t and empirical estimates of the distribution of time between infections. Methods that require data from after time t, such as Wallinga and Teunis (2004), are conceptually and methodologically less suited for near real-time estimation, but may be appropriate for some retrospective analyses. We advise against using methods derived from Bettencourt and Ribeiro (2008), as the resulting Rt estimates may be biased if the underlying structural assumptions are not met. A challenge common to all approaches is reconstruction of the time series of new infections from observations occurring long after the moment of transmission. Naive approaches for dealing with observation delays, such as subtracting delays sampled from a distribution, can introduce bias. We provide suggestions for how to mitigate this and other technical challenges and highlight open problems in Rt estimation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKG was supported by the James S. McDonnell Foundation. LM was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number F32GM134721. ML acknowledges support from the Morris-Singer Fund and from Models of Infectious Disease Agent Study (MIDAS) cooperative agreement U54GM088558 from the National Institute Of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of General Medical Sciences or the National Institutes of Health. LFW acknowledges support from the National Institutes of Health (R01 GM122876). SA, JH, SM, JM, NIB, KS, RNT, SF acknowledge funding from the Wellcome Trust (210758/Z/18/Z). Thanks to Christ Church (Oxford) for funding via a Junior Research Fellowship (RNT). This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under CEIRS Contract No. HHSN272201400005C (SC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not analyze any data from human or animal subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a theoretical study analyzing only synthetic data. All code to generate and analyze the data is publicly available on Github (url provided within the text). https://github.com/cobeylab/Rt_estimation ER -